Gerresheimer substantially increases earnings in second quarter

Duesseldorf (ots) -

- cross reference: The full press release including tables is
available at:
http://www.presseportal.de/dokumente abrufbar -

- Revenues up 2.6% to EUR 335.4m (6.0% at constant exchange
rates)
- Adjusted EBITDA rises 9.1% to EUR 65.1m (14.1% at constant
exchange rates)
- Net income grows by 70.3% to EUR 20.8m
- EUR 0.61 earnings per share higher than prior-year quarter (Q2
2013: EUR 0.34)
- Guidance for financial year 2014 confirmed

Gerresheimer AG substantially increased earnings in the second
quarter of financial year 2014. "High-quality packaging for drugs and
products enabling safe and easy self- medication continues to be
increasingly in demand worldwide. We achieved growth in revenues and
most of all in earnings in the second quarter of this year. This
confirms our guidance for 2014," said Uwe Röhrhoff, Chief Executive
Officer of Gerresheimer AG. Gerresheimer AG is one of the leading
partners to the pharma and healthcare industry worldwide, developing
and producing glass and plastic packaging for drugs and cosmetics
along with complex drug delivery products, such as insulin pens,
asthma inhalers and prefillable syringes.

Gerresheimer again increased revenues as planned in the second
quarter of financial year 2014 (December 1, 2013 to November 30,
2014). Revenues in the second quarter of 2014 came to EUR 335.4m, up
2.6% on the prior-year quarter. At constant exchange rates, revenues
grew by 6.0% compared with the prior-year quarter. The main driver of
revenue growth was the pharmaceutical plastic packaging business.
Similarly, the engineering and tooling business, which tends to
precede series production of medical plastic systems, once again saw
a large increase in revenues. Revenues with prefillable syringe
systems likewise continued to grow.

In the second quarter of 2014, the Company generated adjusted
EBITDA of EUR 65.1m, an increase of 9.1% on the prior-year figure.
The adjusted EBITDA margin was 19.4% in the second quarter,
outperforming the 18.3% margin in the comparative period. Margin
growth spanned all three divisions. Net income for the second quarter
totaled EUR 20.8m, EUR 8.5m higher than net income in the same period
of the prior year. The EUR 0.61 earnings per share was higher than
the figure of EUR 0.34 recorded for the prior-year quarter.

As planned, Gerresheimer incurred capital expenditure of EUR 25.1m
in the second quarter of 2014. Capital expenditure continued to focus
on adding production capacity for medical plastic systems such as
insulin pens and inhalers in Horsovsky Tyn, Czech Republic, and
Peachtree City, USA.

Outlook

The Company continues to anticipate revenue growth of 4% to 6% at
constant exchange rates for financial year 2014. Gerresheimer expects
adjusted EBITDA, as before, to be in a range of between EUR 250m and
EUR 265m at constant exchange rates. Capital expenditure in financial
year 2014 will be on a par with the preceding financial year,
representing some 9% to 10% of exchange rate adjusted revenues.

The Q2 report is online available here:
http://gerresheimer.com/en/investor-relations/reports

The online annual report 2013 is available here:
http://annualreport2013.gerresheimer.com

contact:
Gerresheimer AG
Klaus-Bungert-Strasse 4
40468 Düsseldorf
Germany

Jens Kürten
Director Corporate Communication & Marketing
Telephone +49 211 6181-250
Fax +49 211 6181-241
E-Mail j.kuerten@gerresheimer.com
Internet www.gerresheimer.com